Simrén, J;
Leuzy, A;
Karikari, TK;
Hye, A;
Benedet, AL;
Lantero-Rodriguez, J;
Mattsson-Carlgren, N;
... Ashton, NJ; + view all
(2021)
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Alzheimer's & Dementia
, 17
(7)
pp. 1145-1156.
10.1002/alz.12283.
Preview |
Text
Zetterberg_Alzheimer s Dementia - 2021 - Simr n - The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer s.pdf Download (2MB) | Preview |
Abstract
INTRODUCTION: This study investigated the diagnostic and disease-monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. METHODS: Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants. RESULTS: Phosphorylated-tau181 (P-tau181), neurofilament light, amyloid-β (Aβ42/40), Total-tau and Glial fibrillary acidic protein were altered in AD dementia but P-tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P-tau181 was increased in MCI converters compared to non-converters. Higher P-tau181 was associated with steeper cognitive decline and gray matter loss in temporal regions. Longitudinal change of P-tau181 was strongly associated with gray matter loss in the full sample and with Aβ measures in CU individuals. DISCUSSION: P-tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss. These findings highlight the potential value of plasma P-tau181 as a non-invasive and cost-effective diagnostic and prognostic biomarker in AD.
Type: | Article |
---|---|
Title: | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease |
Location: | United States |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1002/alz.12283 |
Publisher version: | http://dx.doi.org/10.1002/alz.12283 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Alzheimer's disease, magnetic resonance imaging, phosphorylated tau, plasma biomarkers |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
URI: | https://discovery.ucl.ac.uk/id/eprint/10122102 |
Archive Staff Only
View Item |